US Patent 6,303,640: Scope, Claims, and US Patent Landscape (Method of Reducing Side Effects in Diabetes via TZD + Insulin Secretion Enhancer)

What does US 6,303,640 claim at the highest level?

US 6,303,640 claims a combination therapy method in diabetic patients where a thiazolidinedione (TZD) (specified by a broad structural Markush framework) is administered together with an insulin secretion enhancer, with the explicit goal of reducing side effects attributable to the “respective active components.”

The independent claim (Claim 1) is drafted as:

Patient: diabetic patient.
Therapeutic concept: administer a therapeutically effective amount of a TZD-like compound (represented by a formula with broad permissible substituents), in combination with an insulin secretion enhancer.
Effect: “reducing the side effects of respective active components administered to a diabetic patient.”
TZD identity scope: broad structural genus by parameters (R′, Y, A, Q, ring E, L, M, m, n, X) plus a specific proviso carving out one corner of the genus.
Insulin secretion enhancer scope: not limited to any single drug class in Claim 1; later dependent claims enumerate sulfonylureas and specific named examples.

This is not a claim to a new TZD molecule alone. It is a use claim: a method for combination use to modify tolerability/side-effect profile.

What is the claim architecture and how broad is it?

Claim 1 is a wide Markush method claim

Claim 1 contains two major “moving parts”:

TZD compound genus (structural formula parameters).
Insulin secretion enhancer (functionally defined in Claim 1; enumerated in dependent claims).

TZD genus controls (Claim 1)

Claim 1 specifies a compound “represented by the formula” with key variable definitions you provided, including:

Y is one of: —CO—, —CH(OH)—, or —NR3— (R3 is an optionally substituted alkyl group).
X is CH or N.
A is either a bond or C1-7 divalent aliphatic hydrocarbon group.
Q is oxygen atom or sulfur atom.
R′ is an optionally substituted hydrocarbon or heterocyclic group, with an important proviso:
- “with a proviso that R′ does not represent benzopyranyl group when m and n are 0, X represents CH, A represents a bond, Q represents sulfur atom, R1, L and M represent hydrogen atoms and ring E does not have further substituents.”
m is 0 or 1.
n is 0, 1 or 2.
ring E may have 1 to 4 further substituents or be fused/constructed via substitution combined with R1.
L and M are hydrogen or may combine to form a bond.

Net effect: Claim 1 is drafted to capture a broad structural family around a TZD core while excluding a narrow specified benzopyranyl configuration under a narrow parameter combination.

Insulin secretion enhancer definition and later narrowing

Claim 1 requires an “insulin secretion enhancer,” and dependent claims provide examples and lists:

Claim 4: glibenclamide.
Claim 8-9: sulfonylureas, with an extensive named list.
Claim 12: additional enhancer examples (three named compounds).

Dependent claims add named embodiments and narrower pairings

The dependent claims largely do three things:

lock the TZD to a specific active (pioglitazone or troglitazone or a specific named compound),
lock the enhancer to a named agent or enhancer class (glibenclamide or sulfonylureas),
tighten to a particular pair.

What are the explicit claim embodiments (Claims 2–12)?

TZD-specific dependent claims

Claim 2: method according to Claim 1 where the compound of formula (II) is the compound of formula (II) (as you pasted, the detailed formula is missing, so this is a formal dependency rather than a content addition).
Claim 3: compound of formula (II) is pioglitazone (or pharmacologically acceptable salts).
Claim 7: compound of formula (II) is troglitazone (or salts).
Claim 6: compound of formula (II) is 5-[[4-[2(-methyl-2-pyridylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione (or salts).
Claim 5: compound of formula (II) is pioglitazone and enhancer is glibenclamide.

Insulin secretion enhancer-dependent claims

Claim 4: insulin secretion enhancer is glibenclamide.
Claim 8: insulin secretion enhancer is a sulfonylurea.
Claim 9: sulfonylurea is selected from a long list, including:
- tolbutamide, chlorpropamide, tolazamide, acetohexamide,
- 4-chloro-N-[(1-pyrrolidinylamino)carbonyl]-benzenesulfonamide (and ammonium salt),
- glibenclamide, gliclazide,
- 1-butyl-3-metanilylurea, carbutamide, glibonuride,
- glipizide, gliquidone, glisoxepid, glybuthiazole,
- glibuzole, glyhexamide, glymidine, glipinamide,
- phenbutamide, tolcyclamide.
Claim 12: enhancer is selected from:
- N-[[4-(1-methylethyl)cyclohexyl)carbonyl]-D-phenylalanine,
- calcium (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionate dihydrate,
- glimepiride.

R′ heterocycle genus dependent claim

Claim 10: R′ is an optionally substituted heterocyclic group.
Claim 11: R′ is one of a large explicit list of heterocycles (pyridyl/pyrimidinyl/pyridazinyl/pyrazinyl/pyrazolyl/isothiazolyl/isoxazolyl/thiazolyl/oxazolyl/oxadiazolyl/triazolyl/tetrazolyl/benzimidazolyl/indolyl/indazolyl and others), including benzopyranyl.

This claim set means that while Claim 1 excludes a specific benzopyranyl corner case under a narrow condition, Claim 11 still lists benzopyranyl as an allowed R′ in the heterocycle-specific embodiment. The interaction matters for infringement and validity: the exclusion in Claim 1 applies only when the parameter constellation (m,n,X,A,Q,R1,L,M, ring E substitution status) is satisfied. If not, benzopyranyl appears within the broader Markush permission.

What is the practical infringement “core” of US 6,303,640?

From an operational standpoint, the strongest coverage centers on combinations that look like:

TZD: pioglitazone or troglitazone or the named thiazolidinedione derivative.
Enhancer: glibenclamide or other sulfonylureas (e.g., glimepiride, gliclazide, glipizide, tolbutamide, etc.).

The “reducing side effects” element frames the method as a tolerability-improvement use rather than a simple additive efficacy claim. For patent scope, that phrase typically becomes a key limitation: an accused method must be tied to using the combination for side-effect reduction (not merely co-administration for glycemic control). Claim construction will control how that limitation is met.

What does the proviso likely do to the genus scope?

The proviso excludes:

R′ = benzopyranyl
only when simultaneously:
- m = 0 and n = 0
- X = CH
- A = bond
- Q = sulfur
- R1, L, M = hydrogen
- ring E has no further substituents

So the exclusion is narrow:

it is parameter-constrained to a specific structural subset,
it does not broadly remove benzopyranyl from the overall genus,
it primarily blocks one “point” in the Markush space under a narrowly specified structural configuration.

How does this claim set map onto the known antidiabetic drug landscape?

Even without external sourcing of the patent’s bibliographic details (assignee, filing date, expiration), the drug logic is straightforward:

TZDs (pioglitazone, troglitazone, and a related thiazolidinedione derivative) are insulin sensitizers.
Sulfonylureas (glibenclamide, glimepiride, gliclazide, glipizide, etc.) are insulin secretion enhancers.
The claim explicitly covers TZD + insulin secretion enhancer combinations and seeks to protect a side-effect mitigation rationale.

This is consistent with a common clinical and commercial combination strategy in diabetes: pairing an insulin sensitizer with an insulin secretagogue to improve control. US 6,303,640’s differentiator is the explicit side-effect reduction method framing.

US patent landscape: where this patent likely sits in blocking vs. enabling zones

Because you supplied only claim text, not the patent’s bibliographic data (assignee, earliest priority date, prosecution history, family members), a complete US landscape map (continuations, divisionals, related families, expiration-adjusted dates, terminal disclaimers, et al.) cannot be produced from the provided information. The analysis below is limited to landscape logic based on claim content and the typical patenting behavior around TZD + sulfonylurea combinations.

1) Blocking zone (combination method with side-effect reduction framing)

US 6,303,640 can act as a blocker against:

any new fixed or flexible regimen that includes:
- a covered TZD genus (with pioglitazone/troglitazone expressly called out), and
- a covered insulin secretion enhancer (especially sulfonylureas),
where the regimen is asserted or implemented as a side-effect reduction method.

The broader the TZD Markush and the enhancer list, the easier it is for a later generics or combination developer to land inside the claim boundaries unless they change both:

the TZD structure/genus member, and
the enhancer class to a non-included functionally and structurally defined enhancer category,
and possibly the claimed method purpose (side-effect reduction).

2) Easier carve-out zone (if a company shifts enhancer class)

The claim captures “insulin secretion enhancer,” then narrows via dependent claims to:

sulfonylureas (explicit list),
glibenclamide,
glimepiride,
and two other named agents.

So, a strategy that shifts to enhancers that are:

not sulfonylureas,
not the listed named enhancers in dependent claim sets, may reduce risk, but Claim 1’s functional “insulin secretion enhancer” still matters. Even if the drug is not named in dependent claims, it can still fall inside Claim 1 depending on how “insulin secretion enhancer” is construed.

3) Easier carve-out zone (if a company shifts TZD out of the genus)

Claim 3 and Claim 7 explicitly cover pioglitazone and troglitazone. Claim 1 covers a TZD-like structure via parameters.

A company that uses a non-TZD insulin sensitizer (for example, a different class) would fall outside the Claim 1 TZD structural framework, assuming the structural formula does not encompass that alternative class.

Scope summary table (what is clearly in vs. clearly out from the text provided)

Claim element	Covered in US 6,303,640 (from text provided)	Scope type
Method subject	Diabetic patient	Limiting preamble
Core compound	TZD-like compound represented by formula with variables (R′, Y, A, Q, X, ring E, m, n, L, M)	Broad Markush genus
TZD exemplars	Pioglitazone (Claim 3) ; Troglitazone (Claim 7) ; specific thiazolidinedione derivative (Claim 6)	Explicit embodiments
Enhancer	“insulin secretion enhancer” (Claim 1)	Functional term
Enhancer exemplars	Glibenclamide (Claims 4 and 5); sulfonylureas including glibenclamide, glimepiride, gliclazide, glipizide, etc. (Claims 8-9); two additional named enhancers incl. glimepiride (Claim 12)	Dependent enumeration
Side-effect reduction	Expressly required (“reducing the side effects of respective active components”)	Method limitation
Benzopyranyl carve-out	Excludes benzopyranyl only under a narrow constellation of parameters in Claim 1	Narrow proviso

Business implications for R&D and licensing

Combination development

If a program targets TZD + sulfonylurea (especially pioglitazone/troglitazone + glibenclamide or glimepiride), the overlap risk is highest because multiple dependent claims expressly match these pairings.
If a program uses a different insulin sensitizer class, risk drops only if it lies outside the Claim 1 TZD structural parameters.

Clinical positioning and labeling strategy

The “reducing side effects” language implies that:

generic labeling for co-therapy that only claims glycemic efficacy may face different infringement analysis than a regimen designed or presented specifically to reduce side effects from components.
prosecution history and claim construction will govern, but the claim text is built to require the side-effect reduction use.

Generic/combination market entry

A generic that markets a co-formulation or indicates co-administration could still trigger infringement if it practices the patented method use.
The functional “insulin secretion enhancer” term can capture multiple drug classes; dependent claim lists increase clarity for obvious matches but do not limit Claim 1.

Key Takeaways

US 6,303,640 is a method-of-use patent for diabetic patients using a TZD genus (including explicit pioglitazone and troglitazone embodiments) in combination with an insulin secretion enhancer to reduce side effects.
Claim 1 is broad by Markush structure and functional enhancer definition; dependent claims add specific pairings (pioglitazone + glibenclamide) and a long sulfonylurea list.
The benzopyranyl proviso is narrow and applies only under a constrained parameter set; it does not wholesale remove benzopyranyl from the genus.
The most infringement-proximate product/clinical use profiles are TZD + sulfonylurea combinations (especially those explicitly named such as glibenclamide and glimepiride).
Any landscape assessment that stops at molecule identity misses the key limitation: the method is anchored to side-effect reduction, not only combined glycemic control.

FAQs

1) Does US 6,303,640 claim a new drug composition (formulation) or a use?

It claims a method: administering a specified compound genus in combination with an insulin secretion enhancer to a diabetic patient with the purpose of reducing side effects.

2) Are pioglitazone and troglitazone explicitly covered?

Yes. Claim 3 covers pioglitazone and Claim 7 covers troglitazone, each with pharmacologically acceptable salts.

3) Which insulin secretion enhancers are explicitly listed?

The patent explicitly includes glibenclamide, a broad set of sulfonylureas (including tolbutamide, glipizide, gliclazide, glimepiride, tolazamide, and others), and two other named enhancer examples in Claim 12.

4) How restrictive is the benzopyranyl exclusion?

It is narrow: benzopyranyl is excluded only when multiple structural parameters simultaneously meet the specific conditions recited in the proviso.

5) What is the practical strongest claim target for enforcement?

A regimen that practices TZD (especially pioglitazone or troglitazone) plus a sulfonylurea (especially glibenclamide), used with the claimed side-effect reduction objective.

References (cited sources)

[1] US Patent 6,303,640 claim text provided by user.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0861666	⤷ Start Trial	91298	Luxembourg	⤷ Start Trial
European Patent Office	0861666	⤷ Start Trial	300258	Netherlands	⤷ Start Trial
European Patent Office	0861666	⤷ Start Trial	SPC 038/2006	Ireland	⤷ Start Trial
European Patent Office	0861666	⤷ Start Trial	07C0006	France	⤷ Start Trial
European Patent Office	0861666	⤷ Start Trial	CA 2007 00001	Denmark	⤷ Start Trial
European Patent Office	0861666	⤷ Start Trial	SPC/GB07/009	United Kingdom	⤷ Start Trial
European Patent Office	0861666	⤷ Start Trial	C00861666/01	Switzerland	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,303,640

Summary for Patent: 6,303,640